What is Ait Bioscience?
AIT Bioscience, LLC, based in Indianapolis, Indiana, operates as an integrated contract research laboratory. The company specializes in providing continuous process monitoring and real-time quality control for Ligand Binding Assay (LBA) analytics for large molecules and LC-MS/MS analytics for both small and large molecules. These services are crucial for pre-clinical and clinical trials, spanning Phase I through III. By leveraging a state-of-the-art smart electronic laboratory environment, AIT Bioscience offers tailored bioanalytical solutions across all methods. Their expertise extends from pre-IND through investigational new drug (IND) and new drug application (NDA) stages, encompassing robust analytical method development, expert client consultation, efficient sample logistics, and rapid sample analysis.
How much funding has Ait Bioscience raised?
Ait Bioscience has raised a total of $1.4M across 2 funding rounds:
Private Equity
$1M
Debt
$350K
Private Equity (2013): $1M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Key Investors in Ait Bioscience
PPP
Public-Private Partnership
What's next for Ait Bioscience?
The substantial enterprise-level funding and recent strategic investment position Ait Bioscience for accelerated growth and enhanced service delivery. This capital infusion is likely to fuel advancements in their bioanalytical capabilities, potentially expanding their smart electronic laboratory infrastructure and broadening their reach within the pharmaceutical and biotechnology sectors. The company's focus on comprehensive pre-clinical and clinical trial support, coupled with their integrated approach to LBA and LC-MS/MS analytics, suggests a strategic expansion into new therapeutic areas or a deepening of existing client relationships. Future developments may include enhanced R&D initiatives and strategic partnerships to further solidify their market position.
See full Ait Bioscience company page
